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Multicomponent solid forms of active pharmaceutical ingredients represent a
modern method of tuning their physicochemical properties. Typically, salts are
the most commonly used multicomponent solid form in the pharmaceutical
industry. More than 38% are formulated as organic cations. Salt screening is an
essential but demanding step when identifying the most appropriate formula-
tion. The microbatch under-oil crystallization technique of proteins has been
combined with the previously developed high-throughput vapour-diffusion
screening for use as a novel method of primary salt screening of organic cations.
The procedure allows the set up of about 100 crystallization experiments per
30 min. This requires between 17 and 564 mg of screened cationic active
pharmaceutical ingredients, which were of moderate to very high water solublity.
Five distinct organic salts, three of them diverse active pharmaceutical
compounds or the other enantiomer thereof, in the form of chloride salts were
tested. The screening was extremely successful; at least two new single-crystal
structures could be obtained for each particular compound and many more salts
as single crystals were formed compared with our previous vapour-diffusion
method.
1. Introduction
Control over the multicomponent solid form of an active
pharmaceutical ingredient (API) is a modern way of
improving physicochemical properties of the API without
changing its core chemical structure (Schultheiss & Newman,
2009). Nowadays, pharmaceutical salts are the most frequently
used in multicomponent form in a final drug formulation,
corresponding to about 50% of all solid APIs. Positively
charged APIs occur in 38% of those FDA approved drugs
(prior to the end of 2006), in which the drug has a molecular
weight less than 1000 Da (Paulekuhn et al., 2007). The widely
used chloride is increasingly replaced with other anions
(Paulekuhn et al., 2007). The motivation for this development
is based on, for example, lower hygroscopicity or targeting
that part of the gastrointestinal tract where the salt will be the
most soluble (Berge et al., 1977). The choice of salt is a stan-
dard part of any preformulation study (Morissette et al., 2004).
Furthermore, salts other than chlorides can be helpful during
the purification of a product.
The standard salt screenings are time, material and labour
intensive. New forms are normally generated by direct ioni-
zation of the APIs (Morissette et al., 2004; Tamura et al., 2018).
Surprisingly, to the best of our knowledge, only one method of
high-throughput salt screening using ion exchange has been
published (Nievergelt et al., 2018). It is a modification of the
vapour-diffusion crystallization method (VDHT) originally
developed and optimized for macromolecules (McPherson &
Gavira, 2014). In the method developed by us (Nievergelt et
al., 2018), a water-soluble organic cationic salt (normally in
chloride form) is mixed with a water-soluble sodium or
potassium salt to generate a new, less water-soluble salt of the
organic cation with a new anion. Another feasible modifica-
tion of the crystallization procedure is microbatch under-oil
crystallization (Chayen et al., 1992). The biggest advantage of
under-oil crystallization compared with the vapour-diffusion
method is the higher level of concentration that can be
achieved (see Fig. S1 of the supporting information). The
vapour-diffusion method achieves supersaturation by equal-
ization of the water vapour pressure between two different
solutions. The first solution (the drop in which the crystal-
lization shall take place) is normally a 1:1 mixture of the stock
solution of the screened cationic API and the stock solution of
the anion. The second one is a pure stock solution of the
anion. The water activity in the drop is approximately twice
that of the anion stock solution, as this solution has been one-
time diluted by addition of the aqueous solution of the organic
cation. Having a small drop and a huge reservoir with the
stock solution of the anion, which both share the same vapour
phase, the final concentration of the organic cation within the
drop will reach approximately twice the starting concentra-
tion. In contrast, under-oil screening achieves supersaturation
by slow penetration of water through the silicone oil (Fig. S1
of the supporting information). Hence, the screened drop is
slowly concentrated until an almost dry residue is obtained.
Moreover, microbatch under-oil crystallization can be
performed with standard laboratory equipment such as
multichannel pipettes and crystallization plates without the
need for pipetting robots. On the other hand, one could use a
robot for setting up the crystallization plates as has already
been done in the field of protein crystallization (Chayen et al.,
1990; McPherson & Gavira, 2014). Furthermore, using
different vessels, this method might also be upscalable. Note
that the probability of crystallizing one of the starting mate-
rials during under-oil crystallization is higher, rendering the
evaluation more difficult (Baldock et al., 1996).
In this work, we investigated the crystallization of five
organic cations (Fig. 1), two of which are APIs. R,S-
carnitinenitrile chloride and R-carnitinenitrile chloride {[()-
Car]Cl and [()-Car]Cl} are precursors in the synthesis of
carnitine or its derivatives. Carnitine is used in the treatment
of different diseases from neurological problems to diabetes
mellitus. Only the crystal structure of the tetraphenylborate
salts of [()-Car]+ and [()-Car]+ have been reported
previously (Nievergelt et al., 2018). (1S,2R)-(+)-Ephedrine
hydrochloride ([(+)-EphH]Cl) is the other enantiomer of the
naturally occurring (1R,2S)-()-ephedrine, which is employed
for the treatment of bronchial asthma and emphysema.
(1S,2R)-(+)-Ephedrine is, in general, pharmacologically inac-
tive compared with its other enantiomer (Lee, 2011). There
are many structures of salts of the various diastereomers of
ephedrine (Collier et al., 2006; Wu et al., 2012) described in the
Cambridge Structural Database (Groom et al., 2016).
Diltiazem hydrochloride ([DilH]Cl) is a well known calcium
channel blocking agent, which is used for the treatment of
stable angina pectoris and hypertension. Five crystal struc-
tures containing diltiazem have been reported and four of
them are salts (Kojic´-Prodic´ et al., 1984; Tanaka et al., 1992;
Stepanovs et al., 2016). Trazodone hydrochloride ([TrH]Cl) is
being used pharmaceutically as an antidepressant (Davidoff et
al., 1987). The crystal structures of the protonated trazodone
chloride (Fillers & Hawkinson, 1979), iodide and oxalate
(Nievergelt et al., 2018) salts have been reported previously.
2. Experimental
(1S,2R)-(+)-Ephedrine hydrochloride and trazodone hydro-
chloride were obtained from Sigma–Aldrich. R-Carnitine-
nitrile chloride was obtained from Angene Chemical, Hong
Kong, HK. R,S-Carnitinenitrile chloride was obtained from
Frontier Scientific, Logan, UT, USA. Diltiazem hydrochloride
was provided by Zentiva k.s., Prague, CZ. The used silicone oil
(unless otherwise noted) was article number
146153 from Sigma–Aldrich; it has a viscosity
of 50 cSt (1 cSt = 1 mm2 s1) and is normally
used for melting-point and boiling-point
apparatus. This oil was previously used in
under-oil screenings of proteins (Vetting et al.,
2009). For a few experiments, a silicone oil
with a much lower viscosity of 5 cSt was
employed (article number: 317667 from
Sigma–Aldrich). Sodium or potassium salts of
suitable counterions were obtained from
various commercial suppliers. The reason for
choosing either a sodium or potassium salt was
based on the accessibility of one versus the
other (e.g. sodium hydrogen phthalate is not
commercially available, however, its potassium
salt is). In cases when the sodium or potassium
salts were not commercially available, the
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Figure 1
Chemical structures of the screened organic cations in the form of chlorides or
hydrochlorides.
sodium salts were prepared by titration of the corresponding
acids with a sodium hydroxide solution (2M) until a pH of 7
was reached. The solutions of the newly prepared salts were
concentrated with the help of a rotary evaporator and dried by
lyophilization. The water content was determined by
elemental analysis (carbon, hydrogen and nitrogen) of each
new salt. The concentrations of the anion solutions were
chosen such that they were about half saturated. In the case of
high concentrations, lower concentrations of the same anion
were also employed in order to test the influence of the
concentration of the anions.
The screening technique described in this publication
combines the primary salt screening of APIs and growing
single crystals of hits. Silicone oil (100 ml) was added to each
well in a 96 round bottom well costar 3795 plate (Corning
Incorporated, USA). Stock solutions of four organic cations
including two APIs [diltiazem hydrochloride, (R,S)-
carnitinenitrile chloride, (R)-carnitinenitrile chloride, (1S,2R)-
(+)-ephedrine hydrochloride, 5 ml each; 90% maximal
saturation in water] were pipetted with the help of an eight-
channel pipette directly into the silicone oil within the wells.
The drops of these aqueous solutions sank to the bottom of
the well. Afterwards, individual stock solutions of the coun-
terions (5 ml) were added to each well with silicone oil and the
to-be-crystallized organic cation. When trying different
volumes of solutions, volumes smaller than 5 ml of the
concentrated anion solutions were difficult to pipette due to
their high viscosity, yet volumes larger than 5 ml of the analyte
were actually superfluous and wasted stock solutions. In some
cases, it was necessary to combine two separate aqueous drops
with a pipette tip under oil in order to have one common drop.
In every well, there must be just one drop of the mixture,
which is crucial for the under-oil experiment. Initial screenings
were carried out for 147 different conditions with 86 different
counterions (Table S1).
In a second series of experiments, we concentrated on
ephedrine and trazodone as well as on 96 promising anion
solutions (see Table S2). Ephedrine is known to form many
salts (Collier et al., 2006), some of which we did not obtain
with our first series of experiments. Secondly, all studied
cations of the first series were highly soluble or even extremely
soluble in water. In order to have a compound that also
displays moderate but not too high solubility in water, we
selected trazodone hydrochloride, which we had studied in our
previous vapour-diffusion investigation (Nievergelt et al.,
2018). Compared with the 147 conditions used previously, we
eliminated anions that were only soluble at millimolar
concentrations (e.g. sodium dodecylsulfate) or whose solution
became black because of lack of chemical stability (sodium 4-
aminosalicylate). Furthermore, the chosen maximum concen-
tration of the anion salt should approximately correspond to a
half-saturated solution of the salt of that very anion. There-
fore, some of the initial concentrations of the sodium or
potassium salts were increased as we discovered that these
concentrations had been well below half-saturation in our first
series of experiments. Additionally, we used smaller volumes
of the organic cation solution compared with the volumes of
the anion solutions in order to promote anion exchange. For
ephedrine, we mixed 2 ml of 90% saturated ephedrine solution
and 20 ml of counterion solution. For trazodone, we mixed 4 ml
of 90% saturated trazodone solution and 10 ml of counterion
solution. We monitored all wells essentially every day for
30 days and marked the outcome of the crystallizations.
Promising looking crystals were isolated and placed in Infi-
neum V8512 oil as soon as possible as the solutions continued
to become more concentrated. In some cases, it was necessary
to induce crystal growth by scratching the wells with a
dissecting needle.
Single-crystal X-ray diffraction patterns were measured on
a Rigaku-Oxford Diffraction XtaLAB Synergy-S dual source
diffractometer: Kappa-axis four-circle goniometer with a
Dectris Pilatus3 R 200 K hybrid pixel area detector and Cu
and Mo PhotonJet microfocus X-ray sources. The data
collection strategy and data reduction were performed using
CrysAlisPRO (Rigaku Oxford Diffraction, 2015). Crystals
were fished out using a micro-spoon spatula from Bochem
(35781 Weilburg, Germany, article number 3344) also avail-
able at VWR (article number 231–1355). The crystals were
prepared on a glass slide under Infineum V8512 oil and the
single crystals were mounted on top of a 18 mm Mounted
CryoLoop in a CrystalCap Magnetic (Hampton Research).
The structures were solved using SUPERFLIP (Palatinus &
Chapuis, 2007), SIR92 (Altomare et al., 1994) or SHELXT
(Sheldrick, 2015a), and were refined in CRYSTALS (Better-
idge et al., 2003) or SHELXL2014 (Sheldrick, 2015b).
Graphical output was made with the help ofMercury (Macrae
et al., 2008).
3. Results and discussion
Protein micro-batch crystallization (Chayen et al., 1992) was
modified to be used for the salt screening of organic cations.
Initially, we chose four different organic cations for the
screening, two permanent cations [(R,S)-carnitinenitrile
chloride and (R)-carnitinenitrile chloride] and two bases as
their hydrochloride salts [diltiazem hydrochloride and
(1S,2R)-(+)-ephedrine hydrochloride]. Their approximate
solubilities are given in Table 1. Initial screenings were carried
out for 147 different conditions with 86 different counterions
(Table S1). The chosen anions were selected to include many
diverse inorganic and organic anions, many of them fulfilling
research papers
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Table 1










Diltiazem hydrochloride 720  70§ 312 1.44
(R,S)-Carnitinenitrile chloride 1120  106} 486 5.64
(R)-Carnitinenitrile chloride 1300  200} 564 6.54
(1S,2R)-(+)-Ephedrine hydrochloride 257 1} 111 1.15
Trazodone hydrochloride 38.5  0.2} 17 0.085
† For screening 97 conditions. ‡ At 90% saturation. § Determined as described by
Nievergelt et al. (2018). } Value taken from the work by Nievergelt et al. (2018).
the GRAS condition (Select Committee on GRAS
Substances, 2017), some of them were selected because of
their propensity to form crystalline salts. As we have found
previously (Nievergelt et al., 2018) that half-saturated anion
solutions work well, we also employed them here. The
concentration of some selected anion solutions with concen-
trations higher than 2M were halved once or twice in order to
promote crystal growth rather than a powdery precipitate. As
the initially chosen compounds (carnitinenitrile chloride,
diltiazem and ephedrine hydrochloride) all exhibited rather
high solubility and only formed new crystal salts in the
presence of highly concentrated anions, we set up a second
round of optimization. First, we changed the volume ratio of
cation solution to anion solution in the case of ephedrine from
1:1 to 1:10 in order to promote the anion exchange. Secondly,
we selected an additional API, trazodone, that we had already
tested in the vapour-diffusion nano-crystallization technique
(Nievergelt et al., 2018) and that has a 10 lower aqueous
solubility than ephedrine, the organic salt with the lowest
solubility in the current study so far (Table 1). For trazodone,
we chose an API to anion solution volume ratio of 1:2.5.
Finally, we reduced the number of crystallization trials per
analyte in order to efficiently use 96 well plates (for details, see
the Experimental).
The formation of single crystals of the organic cation
together with an anion other than chloride (if present) was
selected as the desired endpoint of the crystallization trials.
The positive results of the crystallization experiments,
including the concentration of the counterion solution used,
are summarized in Table 2. Additionally, the number of the
day on which crystals were first observed is given (e.g. D0:
crystals observed on the day of setting up the experiment). We
have succeeded in the crystallization of at least two salts for
each screened cation. In three cases, we observed crystal-
lization of a supersaturated solution directly after having
touched the drop with a spatula or scratched the well with a
dissecting needle. The resulting
crystals were the new bromide (see
Fig. 2), tetrafluoroborate and iodide
salts of [()-Car]+ as well as the
iodide salt of [()-Car]+. Further-
more, there were three positive hits
with too low-quality crystals for
structural analysis of [()-Car]
bromide, [()-Car] tetraphenyl-
borate and [()-Car] tetraphenyl-
borate. Moreover, we succeeded in
the crystallization of four new salt
forms of diltiazem (see Fig. 2). The
diltiazem crystal structures of the
bromide, the iodide and the nitrate
salts are essentially isostructural
with the published data on the
chloride salt (Kojic´-Prodic´ et al.,
1984). Additionally, we tried to
crystallize the pure solution of the
screened cations in the forms of
chlorides or hydrochlorides using the under-oil technique. In
this way, the unit cells of the crystals of the [DilH]Cl and [(+)-
EphH]Cl salts were found to correspond to the known forms
of the hydrochlorides. [()-Car]Cl crystallized as high-quality
single crystals. Surprisingly, R,S-carnitinenitrile chloride crys-
tallized with two S-carnitinenitrile and one R-carnitinenitrile
cations in the asymmetric unit of the chiral space group P21.
Such a rare system has been described in the literature either
as a pseudo unbalanced crystallization, co-crystals of a race-
mate or unbalanced chiral packing (Fa´bia´n & Brock, 2010;
Albrecht et al., 2010; Wachter et al., 2016; Kotelnikova et al.,
2017; Grothe et al., 2017). The remaining observed negative
crystallization results were either mixtures of NaCl (Fig. S2)
and amorphous residue, amorphous residue only or pure
chlorides (or hydrochlorides) of the tested anions.
As a next step for improving the under-oil method, we
employed a larger volume of anion solution compared with
the analyte solution. This increases the anion to organic cation
ratio and therefore was predicted to favour the formation of
the new salt. Finally, we reduced the number of anion solu-
tions to just 96 selected conditions (ignoring the salt free
condition), allowing one series of screening experiments to be
carried out in just one 96 well plate. We eliminated anions with
a low millimolar solubility that would not promote a quanti-
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Table 2
Obtained single crystals.
Crystals were grown by mixing 5 ml of the organic cation solution and 5 ml of the anion solution unless otherwise
noted. DX: crystals were observed after X days.
Salt providing the new anion Molarity [(+)-EphH]Cl [()-Car]Cl [()-Car]Cl [DilH]Cl [TrazH]Cl
Sodium bromide 4.08 D0† D14‡ D5
Sodium iodide 5.34 D5† D8‡ D11 D6 D1†, §
Sodium tetrafluoroborate 2.00 D10} D3§
Potassium thiocyanate 7.34 D2† D1§
Sodium nitrate 4.61 D30‡, ††, ‡‡ D6 D1§
Sodium dihydrogen phosphate 3.40 D5
Sodium pyrrolidone carboxylate 4.96 D1††
Sodium benzenesulfonate 1.10 D16†, ††
Disodium oxalate 0.138 D6†, †† D1†, §
Disodium malonate 2.97 D16†, ††
Sodium l-malate 2.92 D30††
Potassium sodium l-tartrate 1.40 D30††
No additional salt added D15† D14 D7 D6†
† Published structure, sometimes of the other enantiomer (Hearn & Bugg, 1972; Kojic´-Prodic´ et al., 1984; Collier et al., 2006;
Wu et al., 2012; Nievergelt et al., 2018). ‡ Crystallized after touching the drop with a spatula or scratching the well with a
dissecting needle. § Obtained by mixing 4 ml of the trazodone solution and 10 ml of the anion solution. } Concentration of
sodium tetrafluoroborate was 4.0M. †† Obtained by mixing 2 ml of the ephedrine solution and 20 ml of the anion
solution. ‡‡ Two polymorphs (I† and II) observed.
Figure 2
Left: displacement ellipsoid representation of [DilH][NO3]. Right:
displacement ellipsoid representation of [()-Car]Br. Ellipsoids are
depicted at 50% probability.
tative anion exchange and anions that were determined to be
unstable in an aqueous, aerated solution [such as sodium 4-
aminosalicylate (The Merck Index, 1976)]. Indeed, the
improved method yielded five salts of trazodone, of which
three were novel. The second round of crystallization of
ephedrine with a 1:10 volumetric ratio of analyte solution
versus anion solution gave seven additional salts, of which four
were new. One of the novel structures was a new polymorph of
ephedrinium nitrate, which crystallized in the chiral space
group P21 with two formula units in the asymmetric unit and
unit-cell dimensions of a = 6.0401 (3), b = 29.3553 (8), c =
7.3828 (3) A˚,  = 112.806 (5) and V = 1206.70 (9) A˚3. Later,
three-dimensional crystals (Fig. S15) were produced that were
identified as the known nitrate salt polymorph I (Collier et al.,
2006), which also crystallized in the monoclinic space group
P21, but with just one formula unit in the asymmetric unit and
with unit-cell dimensions of a = 5.536 (5) A˚, b = 6.839 (9) A˚, c
= 15.669 (12) A˚,  = 97.28 (7) and V = 588 (1) A˚3. In poly-
morph I, the ephedrine cation adopts a folded conformation,
while in polymorph II it is in an extended conformation.
Further anions that formed novel crystal structures with
ephedrine, are l-tartrate, which crystallizes as a monohydrate
in the chiral space group P21. The trihydrate has previously
been reported by Collier et al. (2006). Additionally, we
succeeded in crystallizing the monohydrate of l-malate; its
anhydrate form has been described again by Collier. For
trazodone, three novel crystal structures of its protonated
form with either nitrate, tetrafluoroborate or thiocyanate
could be determined. For all wells in which no crystallization
could be observed, the drops were punctured with a spatula or
the wells below the drops scratched with a preparation needle.
Since in a few cases, crystal growth in some over-saturated
drops could be observed after this procedure, we recommend
performing this easy step for all wells in which no crystals have
formed after a few weeks.
In order to study the influence of the ratio of anion to
organic cation, the cation of the salt that provides the final
anion and the used oil, we performed detailed design experi-
ments for two selected anions, iodide and oxalate (Tables S3
and S4). For the crystallization of ephedrinium iodide, the
ratio of ephedrinium to iodide was varied between 1 and 200.
Additionally, lithium, sodium and potassium iodide at the
same concentration were compared in order to assess their
influence on the crystallization of ephedrinium iodide. And
thirdly, the whole series was repeated with a silicone oil
possessing a 10 lower viscosity (5 cSt) than the one
previously used, as d’Arcy and co-workers have shown that
the viscosity of the silicone oil more or less linearly correlates
with the time it takes for the protein crystals to appear
(D’Arcy et al., 1996). The summary of our results of the
crystallization of ephedrinium iodide (Table S3) is as follows.
Crystals were observed within a 5- to 50-fold ratio of iodide to
ephedrinium. At a ratio smaller than 5, there seems to be
insufficient excess iodide present. At a ratio higher than 50,
there was not enough ephedrinium in the drops. While small
differences could be noticed, no clear effects of the cation of
the iodide salt nor the used silicone oil could be established.
For the crystallization of bis-ephedrinium oxalate (Table S4),
the influence of the ratio of oxalate to ephedrinium and the
used silicone oil was studied. The growth of ephedrinium
oxalate crystals could be observed over a wide ratio between
0.01 and 3.3 up to 33.3 (depending on the oil used). If the ratio
of oxalate to ephedrinium was 0.1 or lower, after a number of
days the remaining ephedrinium chloride formed large crys-
tals in both oils.
As a final step, we compared the results of the under-oil
microbatch screening with the VDHT technique (Nievergelt et
al., 2018). The chosen cations for the comparison were [()-
Car]+, [()-Car]+, [(+)-EphH]+ and [TrazH]+ with decreasing
solubilities in this order (see Tables 1 and 3). The under-oil
microbatch screening was able to produce many more crys-
talline salts with an exchanged anion than with the VDHT
screening for any of the four compared cations (see Table 3).
The reason for the superior performance of the under-oil
method most likely lies in the higher supersaturation that can
be achieved with the under-oil method compared with vapour
diffusion.
When analysing the results of our crystallizations, it became
clear that mainly anions that were present in equally high or
higher concentrations than the organic cations, crystallized
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Table 3
Comparison of the results obtained by under-oil and vapour-diffusion (VDHT) methods.
(): no salt crystal was obtained during the screening. Abbreviations: tetraphenylborate: [TPB]; thiocyanate: [SCN]; oxalate: [OXA]2; benzenesulfonate
[BS]; pyrrolidone carboxylate: [Pyrcarb].
Cation to be crystallized [(+)-EphH]+ [()-Car]+ [()-Car]+ [TrazH]Cl
Method Under oil VDHT Under oil VDHT Under oil VDHT Under oil VDHT
Anions Cl Cl [TPB] [TPB] [TPB] [TPB] I I
Br Br Cl  Cl  [OXA]2 [OXA]2
I I Br  Br  NO3 
[SCN] [SCN] I  I  [BF4] 
[OXA]2 [OXA]2 [BF4]








† Two polymorphs obtained.
together with them. The only anion that does not follow this
rule is oxalate. This is in accordance with a report by Stepa-
novs and co-workers, who described a system also containing a
methylammonium ethanol unit. The oxalate salt of propra-
nolol had a 28-fold lower aqueous solubility of the organic
cation when compared with the chloride salt (Stepanovs et al.,
2015). Additionally, we compared the success rate of the
under-oil technique with the classical titration method. Davey
and co-workers (Collier et al., 2006) report the synthesis and
crystallization of 16 salt forms starting from the free base
ephedrine and adding one or half of an equivalent of acid or
diacid. Three different solvents were employed for the
synthesis and subsequent crystal growth. Our direct approach
with the optimized procedure starting from one single solution
of ephedrinium chloride directly yielded single crystals of
eleven salt forms apart from the starting chloride salt. Four of
them had novel crystal structures, including one new poly-
morph of ephedrinium nitrate.
4. Conclusions
The under-oil crystallization technique for proteins was
successfully adapted for use in salt screening of APIs. After an
optimization procedure, the ideal screening involves 96 crys-
tallization batches that consume less than 200 ml of a 90%
saturated solution for each screened API and the experiment
can be set up within ca 30 min. For each screened cation, we
could determine the single-crystal structure of at least two new
salts, each one with a different anion. Five salts of [DilH]+ and
twelve salts of [(+)-EphH]+ were observed and their crystals
grew in sufficient quality for single-crystal X-ray determina-
tion (SCXRD). Two of the four observed crystals of salts of
[()-Car]+ and four of the five of [()-Car]+ crystallized in
sufficient quality for SCXRD. To the best of our knowledge,
this is the first application of the microbatch under-oil crys-
tallization technique for the crystal growth of small molecules.
Finally, the under-oil screening was compared to the vapour-
diffusion method. The under-oil method was found to be much
more effective in generating single crystals for all five
compounds, which were crystallized by both methods (Table
3). Additionally, the under-oil technique does not require the
use of an expensive pipetting robot. In total, 17 new salts of
the studied five cations were prepared. On the other hand, the
under-oil technique consumes a little more material because
the individual experiment requires a higher volume of analyte
solution of between 2 and 5 ml rather than 100 nl in the
vapour-diffusion experiment performed by the liquid handling
robot. As a final remark, we note that the under-oil technique
favours the crystallization of any kind of water-soluble
substance from aqueous solutions.
5. Related literature
The following references are cited in the supporting infor-
mation: Prince (1982); Watkin (1994).
Acknowledgements
We thank Zentiva k.s. for providing the diltiazem hydro-
chloride, and Jeremy Michel for setting up part of the
screening during his lab course. We thank Professor Anthony
Linden and Dr Gu¨nther Steinfeld for a critical reading of the
manuscript.
Funding information
We thank the University of Zu¨rich, the R’Equip programme
of the Swiss National Science Foundation (project No.
206021_164018 to BS), the Czech Science Foundation (grant
No. 16-10035S) and the Specific University Research (MSMT
No. 21-SVV/2018) for financial support.
References
Albrecht, M., Borba, A., Le Barbu-Debus, K., Dittrich, B., Fausto, R.,
Grimme, S., Mahjoub, A., Nedic´, M., Schmitt, U., Schrader, L.,
Suhm, M. A., Zehnacker-Rentien, A. & Zischang, J. (2010). New J.
Chem. 34, 1266–1285.
Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla,
M. C., Polidori, G. & Camalli, M. (1994). J. Appl. Cryst. 27, 435.
Baldock, P., Mills, V. & Stewart, P. S. (1996). J. Cryst. Growth, 168,
170–174.
Berge, S. M., Bighley, L. D. &Monkhouse, D. C. (1977). J. Pharm. Sci.
66, 1–19.
Betteridge, P. W., Carruthers, J. R., Cooper, R. I., Prout, K. & Watkin,
D. J. (2003). J. Appl. Cryst. 36, 1487.
Chayen, N. E., Shaw Stewart, P. D. & Blow, D. M. (1992). J. Cryst.
Growth, 122, 176–180.
Chayen, N. E., Shaw Stewart, P. D., Maeder, D. L. & Blow, D. M.
(1990). J. Appl. Cryst. 23, 297–302.
Collier, E. A., Davey, R. J., Black, S. N. & Roberts, R. J. (2006). Acta
Cryst. B62, 498–505.
D’Arcy, A., Elmore, C., Stihle, M. & Johnston, J. E. (1996). J. Cryst.
Growth, 168, 175–180.
Davidoff, G., Guarracini, M., Roth, E., Sliwa, J. & Yarkony, G. (1987).
Pain, 29, 151–161.
Fa´bia´n, L. & Brock, C. P. (2010). Acta Cryst. B66, 94–103.
Fillers, J. P. & Hawkinson, S. W. (1979). Acta Cryst. B35, 498–500.
Groom, C. R., Bruno, I. J., Lightfoot, M. P. & Ward, S. C. (2016). Acta
Cryst. B72, 171–179.
Grothe, E., Meekes, H. & de Gelder, R. (2017). Acta Cryst. B73, 453–
465.
Hearn, R. A. & Bugg, C. E. (1972). Acta Cryst. B28, 3662–3667.
Kojic´-Prodic´, B., Ruzˇic´-Torosˇ, Z., Sˇunjic´, V., Decorte, E. & Moimas, F.
(1984). Helv. Chim. Acta, 67, 916–926.
Kotelnikova, E. N., Isakov, A. I. & Lorenz, H. (2017). CrystEng-
Comm, 19, 1851–1869.
Lee, M. R. (2011). J. R. Coll. Physicians Edinb. 41, 78–84.
Macrae, C. F., Bruno, I. J., Chisholm, J. A., Edgington, P. R., McCabe,
P., Pidcock, E., Rodriguez-Monge, L., Taylor, R., van de Streek, J. &
Wood, P. A. (2008). J. Appl. Cryst. 41, 466–470.
McPherson, A. & Gavira, J. A. (2014). Acta Cryst. F70, 2–20.
The Merck Index (1976). 9th ed., p. 66. Rahway, New Jersey: Merck &
Co.
Morissette, S. L., Almarsson, O., Peterson, M. L., Remenar, J. F.,
Read, M. J., Lemmo, A. V., Ellis, S., Cima, M. J. & Gardner, C. R.
(2004). Adv. Drug Deliv. Rev. 56, 275–300.
Nievergelt, P. P., Babor, M., Cˇejka, J. & Spingler, B. (2018). Chem. Sci.
9, 3716–3722.
Palatinus, L. & Chapuis, G. (2007). J. Appl. Cryst. 40, 786–790.
Paulekuhn, G. S., Dressman, J. B. & Saal, C. (2007). J. Med. Chem. 50,
6665–6672.
research papers
150 Martin Babor et al.  Microbatch under-oil salt screening of organic cations IUCrJ (2019). 6, 145–151
Prince, E. (1982). Mathematical Techniques in Crystallography and
Materials Science. New York: Springer.
Rigaku Oxford Diffraction (2015). CrysAlisPRO. Version
1.171.38.41. Rigaku Oxford Diffraction, Yarnton, Oxfordshire,
England.
Schultheiss, N. & Newman, A. (2009). Cryst. Growth Des. 9, 2950–
2967.
Select Committee on GRAS Substances (2017). https://www.access-
data.fda.gov/scripts/fdcc/?set=SCOGS.
Sheldrick, G. M. (2015a). Acta Cryst. A71, 3–8.
Sheldrick, G. M. (2015b). Acta Cryst. C71, 3–8.
Stepanovs, D., Jure, M., Gosteva, M., Popelis, J., Kiselovs,
G. & Mishnev, A. (2016). CrystEngComm, 18, 1235–
1241.
Stepanovs, D., Jure, M., Yanichev, A., Belyakov, S. & Mishnev, A.
(2015). CrystEngComm, 17, 9023–9028.
Tamura, Y., Takezawa, H., Domoto, Y. & Fujita, M. (2018). Chem.
Lett. 47, 617–619.
Tanaka, T., Inoue, H., Date, T., Okamura, K., Aoe, K., Takeda, M.,
Kugita, H., Murata, S., Yamaguchi, T., Kikkawa, K., Nakajima, S. &
Nagao, T. (1992). Chem. Pharm. Bull. 40, 1476–1480.
Vetting, M. W., Hegde, S. S. & Blanchard, J. S. (2009).Acta Cryst.D65,
462–469.
Wachter, E., Glazer, E. C., Parkin, S. & Brock, C. P. (2016). Acta
Cryst. B72, 223–231.
Watkin, D. (1994). Acta Cryst. A50, 411–437.
Wu, H., West, A. R., Vickers, M., Apperley, D. C. & Jones, A. G.
(2012). Chem. Eng. Sci. 77, 47–56.
research papers
IUCrJ (2019). 6, 145–151 Martin Babor et al.  Microbatch under-oil salt screening of organic cations 151
